Benefits of statins beyond lipid lowering

Drug Discovery Today: Disease Mechanisms

Volumn 5, Issue 3-4, 2008, Pages

  Merx, M W ^a   Weber, C ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TIROFIBAN;

ACUTE CORONARY SYNDROME; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BACTEREMIA; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG RESPONSE; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOMODULATION; INFECTION; KIDNEY DISEASE; KIDNEY FAILURE; LOW DRUG DOSE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NONHUMAN; REVIEW; RISK REDUCTION; SEPSIS;

EID: 67649401907     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2008.10.001     Document Type: Review

References (57)

1. Goldstein J.L., and Brown M.S. Regulation of the mevalonate pathway. Nature 343 (1990) 425-430
2. Istvan E.S. Bacterial and mammalian HMG-CoA reductases: related enzymes with distinct architectures. Curr. Opin. Struct. Biol. 11 (2001) 746-751
3. Liao J.K., and Laufs U. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 89-118
4. Pedersen T.R., et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Atheroscler. Suppl. 5 (2004) 81-87
5. Sacks F.M., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335 (1996) 1001-1009
6. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339 (1998) 1349-1357
7. Shepherd J., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333 (1995) 1301-1307
8. Downs J.R., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
9. Nissen S.E., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071-1080
10. Ridker P.M., et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am. J. Cardiol. 100 (2007) 1659-1664
11. Kwak B., et al. Statins as a newly recognized type of immunomodulator. Nat. Med. 6 (2000) 1399-1402
12. Kurakata S., et al. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacology 34 (1996) 51-61
13. Romano M., et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest. 80 (2000) 1095-1100
14. Weber C., et al. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J. Am. Coll. Cardiol. 30 (1997) 1212-1217
15. Yoshida M., et al. HMG-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1165-1171
16. Wang C.Y., et al. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol. Med. 14 (2008) 37-44
17. Weitz-Schmidt G., et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 7 (2001) 687-692
18. Hristov M., et al. Reduced numbers of circulating endothelial progenitor cells in patients with coronary artery disease associated with long-term statin treatment. Atherosclerosis 192 (2007) 413-420
19. Colli S., et al. Vastatins inhibit tissue factor in cultured human macrophages: a novel mechanism of protection against atherothrombosis. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 265-272
20. Libby P., and Aikawa M. Lipid lowering therapy in atherosclerosis. Semin. Vasc. Med. 4 (2004) 357-366
21. Aronow H.D., et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 357 (2001) 1063-1068
22. Stenestrand U.W.L., and Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 285 (2001) 430-436
23. Wright R.S., et al. Statin lipid-lowering therapy for acute myocardial infarction and unstable angina: efficacy and mechanism of benefit. Mayo Clin. Proc. 77 (2002) 1085-1092
24. Paradiso-Hardy F.L., et al. The importance of in-hospital statin therapy for patients with acute coronary syndromes. Pharmacotherapy 23 (2003) 506-513
25. Bybee K.A., et al. Effect of concomitant or very early statin administration on in-hospital mortality and reinfarction in patients with acute myocardial infarction. Am. J. Cardiol. 87 (2001) 771-774
26. Newby L.K., et al. Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA 287 (2002) 3087-3095
27. Spencer F.A., et al. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann. Intern. Med. 140 (2004) 857-866
28. Saab F.A., et al. Comparison of outcomes in acute coronary syndrome in patients receiving statins within 24 hours of onset versus at later times. Am. J. Cardiol. 94 (2004) 1166-1168
29. Arntz H.R., et al. Beneficial effects of pravastatin (+/-Colestyramine/Niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). Am. J. Cardiol. 86 (2000) 1293-1298
30. Liem A.H., et al. Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. Eur. Heart J. 23 (2002) 1931-1937
31. Schwartz G.G., and Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
32. Olsson A.G., et al. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur. Heart J. 26 (2005) 890-896
33. Cannon C.P., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350 (2004) 1495-1504
34. Lemos J.A.M., et al. Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292 (2004) 1307-1316
35. Nissen S.E.M. High-dose statins in acute coronary syndromes: not just lipid levels. JAMA 292 (2004) 1365-1367
36. Robinson J.G., et al. Pleiotropic effects of statins: benefit beyond cholesterol reduction ? a meta-regression analysis. J. Am. Coll. Cardiol. 46 (2005) 1855-1862
37. Bauersachs J., et al. Improvement of Left Ventricular Remodeling and Function by Hydroxymethylglutaryl Coenzyme A Reductase Inhibition With Cerivastatin in Rats With Heart Failure After Myocardial Infarction. Circulation 104 (2001) 982-985
38. Sola S., et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J. Am. Coll. Cardiol. 47 (2006) 332-337
39. Kjekshus J., et al. Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med. 357 (2007) 2248-2261
40. GISSI-HF, Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 10.1016/S0140-6736(08)61240-4-10 Epub ahead of print
41. Campese V.M., and Park J. HMG-CoA reductase inhibitors and the kidney. Kidney Int. 71 (2007) 1215-1222
42. Bianchi S., et al. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am. J. Kidney Dis. 41 (2003) 565-570
43. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20.536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
44. Shepherd J., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
45. Amarenco P., et al. High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. 355 (2006) 549-559
46. Amarenco P., et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial. Stroke 38 (2007) 3198-3204
47. Sparks D.L., et al. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's disease cholesterol-lowering treatment (ADCLT) trial. Acta Neurol. Scand. Suppl. 185 (2006) 3-7
48. Liappis A.P., et al. The effect of statins on mortality in patients with bacteremia. Clin. Infect Dis. 33 (2001) 1352-1357
49. Merx M.W., et al. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 109 (2004) 2560-2565
50. Merx M.W., et al. Statin treatment after onset of sepsis in a murine model improves survival. Circulation 112 (2005) 117-124
51. Steiner S., et al. Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 111 (2005) 1841-1846
52. Almog Y., et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 110 (2004) 880-885
53. Hackam D.G., et al. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 367 (2006) 413-418
54. Almog Y., et al. The effect of statin therapy on infection-related mortality in patients with atherosclerotic diseases. Crit. Care Med. 35 (2007) 372-378
55. Kruger P.S., and STATInS Investigators. Statins and sepsis. Br. J. Anaesth. 100 (2008) 862
56. Terblanche M., et al. Statins, bugs and prophylaxis: intriguing possibilities. Crit. Care 10 (2006) 168
57. Fedson D.S. Confronting an influenza pandemic with inexpensive generic agents: can it be done. Lancet Infect. Dis. 8 (2008) 571-576